Frank, you should try Positron @posit.co! It’s superb!

Opinion: Top Studies From EHA 2025 Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

The recent EHA 2025 Congress showcased novel combinations for MDS and AML as well as a novel formulation of a drug for B-ALL: an opinion piece by @ashkishtaagri.bsky.social of @vanderbilt.edu shorturl.at/RkY2M #EHA2025 #leusm #mdssm

Dr Ashwin Kishtagari’s Top 4 Picks From SOHO 2025 Ashwin Kishtagari, MD, shares his top 4 picks from the abstracts presented at the 13th annual meeting of the Society of Hematologic Oncology.

Dr Ashwin Kishtagari (@ashkishtaagri.bsky.social) of @vumedicine.bsky.social shares his top picks from #SOHO2025. #SOHO25 Read about them here:
www.cancertherapyadvisor.com/features/soh...

Thank you to our fearless leader and incredible mentor @AlexBickMDPhD!! Forever grateful to dream team @rheumrob
@yash_pershad
@DrFlashHeart
@brettheimlich
@LeoLuoMD
@FerrellLabVUMC
@SavonaNashville
@YaominXu1

SAMPLE SIZE EXAMPLES for cytopenia prevention trials:

High-risk CHIP patients (≥4 factors):

40% drug efficacy → 544 patients total (80% power)
60% drug efficacy → 200 patients total (80% power)

Compare this to 50,000+ needed for myeloid neoplasm endpoints!

For clinical trial design in CHIP prevention trials we need

Before our study: Need 50,000+ patients, 10+ years for MN endpoint

After our study: Need 400-1,000 patients, 2-3 years for cytopenia endpoint

Following @dpsteensma's vision of actionable CHIP endpoints!

TET2 mutations → ↑ cytopenia risk (HR=1.19)

Spliceosome genes (SF3B1, SRSF2) → ↑↑ risk (HR=1.93)

TP53 pathway → ↑ risk (HR=1.28)

IDH1/2 mutations → ↑↑ risk (HR=2.24)

Building on @LDWeeks_MD @NEJMEvidence
work on CHIP risk prediction!

We identified 7 key risk factors for cytopenia in CHIP patients:

Age ≥65 (HR=1.41)
Male sex (HR=1.45)
Smoking (HR=1.17)
≥2 mutations (HR=1.95)
High-risk genes (HR=1.48)
MCV ≥100 fL (HR=2.12)
RDW ≥15% (HR=2.59)

MASSIVE SCALE gives us confidence:

805,249 participants (All of Us, BioVU, UK Biobank)
9374 CHIP cases + 24749 controls
Follow-up: 2006-2023 (up to 17 years!)
190 myeloid neoplasms, 4,151 cytopenias

The largest longitudinal CHIP study ever conducted!

Previous landmark studies by @SJaiswal_MD (NEJM 2014) and Genovese et al. (NEJM 2014) showed CHIP affects 10-20% of people >70 years, with ~0.5-1% annual myeloid neoplasm.

But designing prevention trials seemed IMPOSSIBLE due to huge sample sizes needed.

Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis: a multi-biobank case-control study Cross sectional studies have demonstrated patients with clonal hematopoiesis of indeterminate potential (CHIP) are at increased risk of developing mul…

I am thrilled to share our new publication in @eclinicalmed.bsky.social co-led with a superb VUMC IM resident James Brogan: "Incident cytopenia and risk of subsequent myeloid neoplasm in age-related clonal hematopoiesis"